DREAMM Trial Update - Blenrep in Myeloma Trials | Natalie Callander, MD | ASH 2021

DREAMM-5 Study of BLENREP (belantamab mafodotin) Combined with Nirogacestat in RRMM patientsПодробнее

DREAMM‑3 - Blenrep (Belmaf) Vs PomDex For Relapsed/Refractory Myeloma | Katja Weisel, MD | ASCO 2023Подробнее

Results of DREAMM-4: safety and efficacy of belantamab mafodotin with pembrolizumab in R/R myelomaПодробнее

Belantamab mafodotin: a potential new SoC in second-line myeloma based on the DREAMM trialsПодробнее

Vaccinations & iStopMM Trial | Natalie Callander, MD | IMS 2022Подробнее

Natalie Callander, MD, Discusses Melflufen Approval for Relapsed/Refractory Multiple MyelomaПодробнее

Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myelomaПодробнее

Natalie Callander, MD on the new GSK Antibody Drug Conjugate Immunotherapy — IMW 2019Подробнее

Transplant trials in myeloma: EMN02 and BMT CTN 0702Подробнее

DREAMM-2 & DREAMM-5: belantamab mafodotin for myelomaПодробнее

A New Target for CAR-T Therapy in Myeloma - GPRC5D | Fredrik Schjesvold, MD | ASH 2021Подробнее

Dr. Cohen on the DREAMM-2 TrialПодробнее

DREAMM-2: update on belantamab mafodotin in R/R myelomaПодробнее

Belantamab Mafodotin + Inducible T-Cell Co-Stimulator Agonist Combination Therapy in Pts w/RRMMПодробнее

MRD highlights from the IMW meetingПодробнее

The current state of MRD-based therapy for myelomaПодробнее

MajesTEC-2 update: teclistamab plus lenalidomide in R/R multiple myelomaПодробнее

The DREAMM-5 PLATFORM trialПодробнее